Devonian Health Group closes $334,500 private placement

Devonian Health Group Inc. (TSXV: GSD) (OTCQB: DVHGF) completed a non-brokered private placement raising $334,500.33 in gross proceeds, according to a company statement.

The biopharmaceutical company issued 1,967,649 units at $0.17 per unit. Each unit includes one common share and one warrant, with warrants exercisable at $0.17 per share for 24 months from the issuance date.

The company paid $14,166.68 in cash finder's fees related to the offering. The shares and warrants are subject to a four-month hold period ending February 23, 2026, under Canadian securities laws. The offering requires final approval from the TSX Venture Exchange.

Devonian plans to use the proceeds primarily for working capital related to corporate overhead and research and development activities. The company develops prescription drugs targeting inflammatory diseases.

The company also announced that Dr. André Boulet, Chairman and CEO, will present at the ThinkEquity Conference on October 30, 2025, at the Mandarin Oriental in New York City. The presentation is scheduled for 12:30 pm at the Lotus Suite West.

The conference brings together institutional investors, analysts, and growth-oriented companies for presentations and networking opportunities. Institutional investors can contact the company and register on the conference website to request meetings with management.

You May Also Be Interested In

• Parabilis Medicines closes $770.5 million IPO and concurrent private placement
• Sonida Senior Living (SNDA) files for 17.11M share offering by selling stockholders
• Supermicro prices $7 billion equity financing to fund AI server orders